On Tuesday, Triangle Petroleum Corporation (NYSEMKT:TPLM)’s shares declined -9.13% to $5.26.
Triangle Petroleum Corporation (TPLM) provides an operational update and reports its fourth quarter fiscal year 2015 and full fiscal year 2015 (“FY 2015″) results for the period ended January 31, 2015.
Highlights for Fiscal Year 2015
Raised volumes in FY 2015 to 4,176 Mboe (+116% y/y) as contrast to 1,929 Mboe in fiscal year 2014 (“FY 2014″). Average daily production rose to 11,441 Boepd in FY 2015, or 2% above the high end of our FY 2015 guidance range of 10,200-11,200 Boepd, from 5,286 Boepd in FY 2014
Triangle Petroleum Corporation is engaged in the acquisition, exploration, development, and production of unconventional shale oil and natural gas resources in the Bakken Shale and Three Forks formations in the Williston Basin of North Dakota and Montana.
FMSA Holdings Inc (NYSE:FMSA)’s shares dropped -9.02% to $8.27.
FMSA Holdings Inc (FMSA) declared that it anticipates releasing its first-quarter 2015 earnings before the New York Stock Exchange opens on Tuesday May 12, 2015. The Company will hold a conference call for investors on May 12, 2015 at 10 a.m. Eastern Time. The call will be hosted by Jenniffer Deckard, president and chief executive officer, Christopher Nagel, chief financial officer and Van Smith, executive vice president responsible for proppant sales, marketing and new product development.
FMSA Holdings Inc., together with its auxiliaries, provides sand-based proppant solutions for exploration and production companies to enhance the productivity of their oil and gas wells. It operates in two segments, Proppant Solutions and Industrial & Recreational (I&R) Products.
At the end of Tuesday’s trade, CEL-SCI Corporation (NYSEMKT:CVM)‘s shares dipped -8.99% to $0.810.
CEL-SCI Corporation (CVM) declared that Aintree University Hospital, in Liverpool, England, has become a clinical site for the Company’s global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This is the first center to join the Multikine Phase III study in the UK.
Aintree University Hospital is a large teaching hospital in Liverpool providing a range of acute and non-acute specialties. The hospital offers specialist services with a world-class reputation to a population of 1.5 million residents across the Northwest of England. The Principal Investigator for the trial site is Professor Richard Shaw. He serves as Honorary Consultant in Oral & Maxillofacial / Head and Neck Surgery at Aintree University Hospital and is a surgeon specializing in head and neck cancers at the University of Liverpool.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The companys lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer.
Halcon Resources Corp (NYSE:HK), ended its Tuesday’s trading session with -8.84% loss, and closed at $1.65.
Halcon Resources Corp (HK) declared that it has priced $700million in aggregate principal amount of senior secured notes due2020 in a private offering. The Notes will bear interest at a rate of 8.625% per annum and will be issued atpar. The Notes offering was raised from the formerly declared $500 million aggregate principal amount. The Notes will be secured by second-precedingity liens on substantially all ofHalcon’s and its partner guarantors’ assets that secure the Company’s senior secured revolving credit facility.
Halcón Resources Corporation, an independent energy company, is engaged in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
